Publications by authors named "Christina Proescholdt"
Article Synopsis
- A literature review identified clinical trials and real-world studies on stage IV NSCLC patients who progressed after platinum-based chemotherapy, using EMBASE and MEDLINE databases from 2017 to 2021.
- The review included 15 publications, showing varied sample sizes and indicating that eight of the nine clinical trials had an overall response rate of ≥15%, while median progression-free survival (PFS) ranged from 1.9 to 6.8 months.
- The findings highlighted the limited treatment response and significant adverse effects for these patients, emphasizing the need for better and more tolerable treatment options.
Background: To date, there has been no large-scale, real-world study of the health-related quality of life outcomes for patients using tumor treating fields (TTFields) therapy for glioblastoma (GBM) treatment.
Methods: A survey was mailed to 2,815 patients actively using TTFields for treatment of GBM in the USA ( = 2,182) and Europe ( = 633). The survey included patient-reported demographic and clinical information, as well as EuroQol's EQ-5D-5L and visual analogue scale (EQ-VAS) overall health score.